Y-mAbs Therapeutics (NASDAQ:YMAB) Now Covered by Truist Financial

Equities research analysts at Truist Financial assumed coverage on shares of Y-mAbs Therapeutics (NASDAQ:YMAB) in a research report issued on Friday, Benzinga reports. The firm set a “buy” rating and a $21.00 price target on the stock. Truist Financial’s target price would suggest a potential upside of 70.32% from the company’s current price.

Several other equities analysts have also recently issued reports on YMAB. Canaccord Genuity Group lifted their price objective on Y-mAbs Therapeutics from $22.00 to $26.00 and gave the company a “buy” rating in a research note on Monday, March 4th. BMO Capital Markets boosted their target price on Y-mAbs Therapeutics from $16.00 to $26.00 and gave the stock an “outperform” rating in a research note on Monday, March 4th. Finally, HC Wainwright increased their price target on shares of Y-mAbs Therapeutics from $21.00 to $22.00 and gave the company a “buy” rating in a research note on Monday, May 13th. Two research analysts have rated the stock with a sell rating and five have issued a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $17.86.

Y-mAbs Therapeutics Price Performance

Shares of YMAB stock opened at $12.33 on Friday. The company has a market capitalization of $541.04 million, a PE ratio of -25.16 and a beta of 0.69. The firm’s 50-day moving average is $13.13 and its two-hundred day moving average is $12.74. Y-mAbs Therapeutics has a 12 month low of $4.60 and a 12 month high of $20.90.

Y-mAbs Therapeutics (NASDAQ:YMAB) last released its quarterly earnings results on Tuesday, May 7th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.03). Y-mAbs Therapeutics had a negative net margin of 25.64% and a negative return on equity of 21.40%. The firm had revenue of $19.93 million for the quarter, compared to analysts’ expectations of $22.06 million. Sell-side analysts forecast that Y-mAbs Therapeutics will post -0.45 EPS for the current year.

Insider Buying and Selling

In other news, insider Thomas Gad sold 35,000 shares of the firm’s stock in a transaction that occurred on Monday, June 10th. The shares were sold at an average price of $12.03, for a total transaction of $421,050.00. Following the transaction, the insider now directly owns 197,681 shares in the company, valued at $2,378,102.43. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In related news, CFO Bo Kruse sold 31,371 shares of the stock in a transaction on Friday, May 31st. The stock was sold at an average price of $12.07, for a total transaction of $378,647.97. Following the completion of the sale, the chief financial officer now directly owns 210,877 shares of the company’s stock, valued at $2,545,285.39. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Thomas Gad sold 35,000 shares of the business’s stock in a transaction on Monday, June 10th. The shares were sold at an average price of $12.03, for a total transaction of $421,050.00. Following the completion of the transaction, the insider now directly owns 197,681 shares in the company, valued at $2,378,102.43. The disclosure for this sale can be found here. Insiders have sold 99,444 shares of company stock worth $1,203,925 in the last quarter. 21.50% of the stock is owned by insiders.

Institutional Trading of Y-mAbs Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. GSA Capital Partners LLP lifted its position in Y-mAbs Therapeutics by 208.3% in the third quarter. GSA Capital Partners LLP now owns 137,299 shares of the company’s stock valued at $748,000 after purchasing an additional 92,765 shares during the period. Campbell & CO Investment Adviser LLC purchased a new stake in shares of Y-mAbs Therapeutics in the fourth quarter valued at approximately $562,000. Trexquant Investment LP grew its holdings in Y-mAbs Therapeutics by 417.5% during the third quarter. Trexquant Investment LP now owns 76,585 shares of the company’s stock worth $417,000 after acquiring an additional 61,785 shares during the period. Los Angeles Capital Management LLC grew its holdings in Y-mAbs Therapeutics by 17.3% during the fourth quarter. Los Angeles Capital Management LLC now owns 356,530 shares of the company’s stock worth $2,432,000 after acquiring an additional 52,610 shares during the period. Finally, Sapient Capital LLC acquired a new stake in Y-mAbs Therapeutics in the fourth quarter valued at $298,000. Hedge funds and other institutional investors own 70.85% of the company’s stock.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.